Trinity Biotech PLC (TRIB) stock
TRIBNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$6.01+0.63 (+11.81%)
Close on Nov 17, 2026Market cap $112.45MP/E –Yield –
Trinity Biotech price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Trinity Biotech's price to sales ratio was 2.5× on Nov 11, 2026, against 9.1× a year earlier. Over the last 5 years it ranged from 2.5× to 12.8×, with a median of 5.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.5× | −4.5 |
| 2025 | Dec 31, 2025 | 6.9× | +3.4 |
| 2024 | Dec 31, 2024 | 3.6× | −0.5 |
| 2023 | Dec 29, 2023 | 4.1× | +0.7 |
| 2022 | Dec 30, 2022 | 3.4× | −0.6 |
| 2021 | Dec 31, 2021 | 4.0× | −28.2 |
| 2020 | Dec 31, 2020 | 32.2× | +23.9 |
| 2019 | Dec 31, 2019 | 8.3× | −10.4 |
| 2018 | Dec 31, 2018 | 18.6× | −24.8 |
| 2017 | Dec 29, 2017 | 43.5× | −13.3 |
| 2016 | Dec 30, 2016 | 56.8× | – |
See a number that looks wrong?